Olmetec Use In Pregnancy & Lactation

USE IN PREGNANCY: When used in pregnancy during the second and third trimesters, drugs that act directly on the renin angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, Olmesartan medoxomil should be discontinued as soon as possible. See Fetal/Neonatal Morbidity and Mortality as previously mentioned and PRECAUTIONS.
Pregnancy: Use of drugs that act directly on the RAS during the second and third trimesters of pregnancy has been associated with fetal injury and even death. Patients who become pregnant whilst using olmesartan medoxomil should discontinue treatment as soon as possible.
If Olmetec is used during pregnancy, or if the patient becomes pregnant while taking Olmetec, the patient should be apprised of the potential hazard to a fetus. Should exposure to Olmetec have occurred from the second trimester forward, ultrasound examinations of the renal function and of the skull are recommended. Newborns exposed to angiotensin II antagonists in utero must be closely monitored for the occurrence of hypotension, oliguria, and hyperkalaemia. See Fetal/Neonatal Morbidity and Mortality under WARNINGS.
Lactation: It is not known whether olmesartan is excreted in human milk, but olmesartan is secreted at low concentration in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.